DEFA14A: Xilio Therapeutics Secures $50 Million in Public Offering to Extend Cash Runway Through Q3 2026

Xilio Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $50.0 million underwritten public offering of pre-funded and common stock warrants to fund operations through Q3 2026.

Summary

• Xilio Therapeutics priced an underwritten public offering of pre-funded warrants and common stock warrants, expecting approximately $50.0 million in gross proceeds.
• The offering includes pre-funded warrants to purchase 66,676,000 shares of common stock, and Series A, Series B, and Series C warrants, each to purchase 66,676,000 shares of common stock.
• The combined public offering price for one pre-funded warrant and accompanying common stock warrants is $0.7499.
• The company estimates net proceeds from the offering to be approximately $46.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.
• If all Series B and Series C warrants are exercised in cash at their exercise price, the company could receive additional gross proceeds of approximately $100.0 million.
• Xilio intends to use the net proceeds to advance the development of its product candidates and for working capital requirements and other general corporate purposes.
• The company estimates that its existing cash and cash equivalents, combined with the net proceeds from this offering, will fund operations through the end of the third quarter of 2026.
• The exercisability of the pre-funded warrants and common stock warrants is subject to stockholder approval to increase the number of authorized shares of common stock, as the company's current certificate of incorporation does not have sufficient authorized shares for full exercise.

Sentiment

Score: 6

Explanation: The capital raise provides essential funding and extends the cash runway for a clinical-stage biotech, which is a positive for operational continuity. However, the significant potential for dilution from the large number of warrants and the contingency on stockholder approval for authorized shares introduce notable negative aspects and future uncertainty, balancing the overall sentiment to cautiously positive.

Positives

• The offering secures approximately $46.6 million in net proceeds, providing crucial funding for a clinical-stage biotechnology company.
• The capital raise is expected to extend the company's cash runway through the end of the third quarter of 2026, supporting ongoing product development and operations.
• The inclusion of Series B and Series C warrants offers a potential for an additional $100.0 million in gross proceeds if fully exercised, providing future funding flexibility.

Negatives

• The offering involves a significant potential for dilution, as it includes pre-funded warrants and three series of common stock warrants, totaling 266,704,000 shares if all are exercised.
• The exercisability of the warrants is contingent upon stockholder approval to increase the number of authorized shares of common stock, introducing a degree of uncertainty.
• The company's current certificate of incorporation does not have a sufficient number of authorized shares to cover the full exercise of all warrants, necessitating stockholder action.
• Series B and Series C warrants are subject to offset and cancellation based on the amount of non-dilutive capital received by the company, which could reduce the actual proceeds from these warrants.

Risks

• The company's cash runway estimate through Q3 2026 is based on assumptions that may prove incorrect, potentially leading to an earlier exhaustion of available capital resources.
• There is no assurance that any of the warrants will be exercised for cash or at all, meaning the potential additional $100.0 million in gross proceeds from Series B and C warrants is not guaranteed.
• The common stock warrants may expire without being exercised, limiting the potential for future capital inflow.
• Failure to obtain stockholder approval to increase authorized shares of common stock would prevent the exercise of the pre-funded and common stock warrants.
• Future equity issuances (with certain exceptions) between the offering date and December 1, 2026, are subject to a minimum purchase price of $1.50 per share, which could be reduced to $1.00 if a majority of pre-funded warrants are exercised by December 1, 2025, potentially impacting future capital raising flexibility.

Future Outlook

Xilio Therapeutics anticipates that the net proceeds from this offering, combined with its existing cash and cash equivalents, will be sufficient to fund its operating expenses and capital expenditure requirements through the end of the third quarter of 2026. This estimate is based on current plans and assumptions, which the company cautions may prove to be incorrect, potentially leading to an earlier depletion of capital resources.

Management Comments

• Xilio Therapeutics, Inc. is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer.
• Xilio intends to use the net proceeds received from the offering to advance the development of its product candidates and for working capital requirements and other general corporate purposes.

Industry Context

This public offering is a common financing strategy for clinical-stage biotechnology companies like Xilio Therapeutics, which are typically pre-revenue and require substantial capital to fund their research and development activities, particularly clinical trials for novel therapies. The capital raise aims to extend the company's operational runway, a critical factor in the capital-intensive drug development industry, allowing it to continue advancing its immuno-oncology product candidates.

Corporate Governance

Stakeholder Impact

• Shareholders face significant potential dilution due to the issuance of a large number of pre-funded and common stock warrants (totaling 266,704,000 shares if fully exercised), which will increase the outstanding share count.
• The company's operations are positively impacted by the extended cash runway through Q3 2026, enabling continued funding for research, development, and general corporate purposes.
• The need for stockholder approval to increase authorized shares places a direct responsibility on current shareholders to enable the full exercisability of the issued warrants.

Next Steps

• Closing of the underwritten public offering, expected on or about June 5, 2025.
• Stockholder meeting on June 10, 2025, to vote on increasing the number of authorized shares of common stock.
• If stockholder approval is obtained, filing a corresponding certificate of amendment to the company's certificate of incorporation.
• Continued advancement of the company's product candidates using the raised capital.

Key Dates

Recommendation

Keywords

Xilio Therapeutics, XLO, Public Offering, Warrants, Pre-funded Warrants, Series A Warrants, Series B Warrants, Series C Warrants, Capital Raise, Biotechnology, Immuno-oncology, SEC Filing, Cash Runway, Dilution, Stockholder Approval